Gestational Glucose Tolerance and Maternal Metabolic Profile at 3 Years Postpartum

Department of Nutrition , Harvard University, Cambridge, Massachusetts, United States
Obstetrics and Gynecology (Impact Factor: 5.18). 11/2011; 118(5):1065-73. DOI: 10.1097/AOG.0b013e3182325f5a
Source: PubMed


To estimate the independent effect of gestational impaired glucose tolerance, defined as a single abnormal oral glucose tolerance test value, on metabolic dysfunction at 3 years postpartum.
We used multiple linear regression to measure associations between glucose testing during pregnancy and metabolic markers at 3 years postpartum in Project Viva, a prospective cohort study of maternal and infant health. We compared metabolic measures at 3 years postpartum among four groups: normal glucose challenge test (less than 140 mg/dL, n=461); abnormal glucose challenge test but normal glucose tolerance test (n=39); impaired glucose tolerance (a single abnormal glucose tolerance test value, n=21); and gestational diabetes mellitus (n=16).
Adjusting for age, race, parity, parental history of diabetes, and maternal body mass index at 3 years postpartum, we found women with gestational diabetes mellitus had lower adiponectin (11.2 ng/mL compared with 20.7 ng/mL) and higher homeostatic model assessments of insulin resistance (3.1 compared with 1.3) and waist circumference (91.3 cm compared with 86.2 cm) compared with women with impaired glucose tolerance or normal glucose tolerance. Women in both the impaired glucose tolerance and gestational diabetes mellitus groups had lower high-density lipoprotein (gestational diabetes mellitus 44.7 mg/dL; impaired glucose tolerance 45.4/dL compared with normal glucose tolerance 55.8 mg/dL) and higher triglycerides (gestational diabetes mellitus 136.1 mg/dL; impaired glucose tolerance 140.1 mg/dL compared with normal glucose tolerance 78.3) compared with women in the normal glucose tolerance group. We found the highest values for hemoglobin A1c (gestational diabetes mellitus 5.1%, impaired glucose tolerance 5.3%, normal glucose tolerance 5.1%) and high-sensitivity C-reactive protein (gestational diabetes mellitus 1.4 mg/dL, impaired glucose tolerance 2.2 mg/dL, normal glucose tolerance 1.0 mg/dL) among women with impaired glucose tolerance.
Gestational diabetes mellitus and impaired glucose tolerance during pregnancy are associated with persistent metabolic dysfunction at 3 years postpartum, independent of other clinical risk factors.

Download full-text


Available from: Ken P Kleinman
  • Source
    • "The pathogenesis of GDM is very similar to that of type 2 diabetes (T2D), in which both pancreatic insulin release and chronic insulin resistance have roles. GDM and impaired glucose tolerance during pregnancy are shown to be associated with future metabolic dysfunction and diabetes separate from other clinical risk factors [3]. The GDM patients may also show early markers of vascular disease such as endothelial dysfunction [4] which may make them susceptible to premature atherosclerosis and coronary heart disease. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Gestational diabetes mellitus (GDM) is a common pregnancy condition. In this study, the risk of having a history of previous GDM (pGDM) on serum homocysteine level was assessed METHODS: Biomedical parameters, serum homocysteine, Insulin, homeostatic model assessment (HOMA)in women with (n = 52) and without pGDM (n = 51) were assessed. According to their current status of Oral Glucose Tolerance Test (GTT), the participants in each group were divided into two subgroups of normal or impairedGTT. Mean serum homocysteine in normal women was 8.56 +/- 3.19 vs 11.44 +/- 7.34 mumol/L (p < 0.01) in women with pGDM. Two groups had significant differences in respect to serum insulin levels (8.35 +/- 5.12vs12.48 +/- 5.44, p < 0.002), and HOMA-IR (1.90 +/- 1.30vs2.91 +/- 1.30, p < 0.002). In women without pGDM, serum homocysteine in normal and impaired GTT were 7.60 +/- 1.69 and 10.52 +/- 3.65 mumol/L (p = 0.03), respectively, while in women with pGDM, the figures were 8.38 +/- 2.52 and 14.00 +/- 10.17 (p < 0.01), respectively. In multi regression analysis an association between history of GDM and homocysteine levels was presented (OR: 7.71, 95% CI: 1.67-35.42, p < 0.001). A trend of elevation of homocysteine is presented in women with pGDM, that is more prominent in women with impaired GTT, and shows a significant correlation with history of GDM. Further studies with larger sample size are suggested.
    Full-text · Article · Jul 2013 · Journal of Diabetes and Metabolic Disorders
  • Source
    • "Maternal glucose values from the screening and diagnostic tests were obtained from the KPNC regional laboratory database, which captures all laboratory tests and results performed at the KPNC regional laboratory. Women were classified as having GDM if two or more of the four plasma glucose values obtained during the diagnostic test were abnormal according to the American Diabetes Association criteria (20) used during the study period (plasma glucose thresholds: fasting 5.3 mmol/L [95 mg/dL], 1-h glucose 10.0 mmol/L [180 mg/dL], 2-h glucose 8.6 mmol/L [155 mg/dL], and 3-h glucose 7.8 mmol/L [140 mg/dL]; gestational IGT glucose challenge test ≥140 mg/dL; and OGTT with only one abnormal result) (7). "
    [Show abstract] [Hide abstract]
    ABSTRACT: To examine whether the association between gestational diabetes mellitus (GDM) and BMI category varies by racial/ethnic group. In a cohort of 123,040 women without recognized pregravid diabetes who delivered babies between 1995 and 2006 at Kaiser Permanente of Northern California, we examined racial/ethnic disparities in the prevalence of GDM by BMI category and the population-attributable risk (PAR) associated with overweight/obesity. Among all racial/ethnic groups, the age-adjusted prevalence of GDM increased with increasing BMI (kg/m(2)) category. However, Asian and Filipina women had a prevalence of GDM of 9.9 and 8.5%, respectively, at a BMI of 22.0-24.9 kg/m(2), whereas in Hispanic, non-Hispanic white, and African American women, the prevalence of GDM was >8.0% at a higher BMI, such as 28-30, 34-36, and ≥37 kg/m(2), respectively. The estimated PARs suggest that the percentage of GDM that could be prevented if all pregnant women were of normal weight (BMI <25.0 kg/m(2)) ranging from 65% for African American women to only 23% among Asian women. Clinicians should be aware that the BMI thresholds for increased risk of GDM varies by racial/ethnic group and that the risk is high even at relatively low BMI cutoffs in Asian and Filipina women. Asian women may benefit from different prevention strategies in addition to weight management.
    Full-text · Article · May 2012 · Diabetes care
  • [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of gestational diabetes is increasing, with higher obesity in the pregnant population, lifestyle changes and migration thought to underlie this. Recent large studies, such as the MiG, HAPO and ACHOIS trials, have furthered our understanding of both the implications of the disease and the management options available. Previous CEMACH (Confidential Enquiries into Maternal and Child Health) studies of diabetes in pregnancy have shown a significant proportion of patients receiving sub-optimal care. We aim to summarise the current standard of management strategies in pregnancy, whilst acknowledging controversies and limitations in the existing evidence. Antenatal management involves service organisation to provide multi-disciplinary team reviews to address glycaemic control, fetal monitoring and associated conditions such as obesity and hypertensive disorders of pregnancy. The use of diet, exercise, oral hypoglycaemic agents and insulins will be discussed, along with specific considerations for the management of preterm labour and administration of corticosteroids for fetal lung maturity. The timing and management of labour, including mechanisms of delivery, will be covered, including neonatal considerations and the use of breast feeding. Finally, a discussion of appropriate post delivery care will consider the prevention of, and screening for, the development of type 2 diabetes.
    No preview · Article · May 2012 · Current diabetes reviews
Show more